Sudden Hearing Loss Associated with Tacrolimus in a Kidney‐Pancreas Allograft Recipient
Authors:
- 1 July 1999
- journal article
- case report
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 19 (7) , 891-893
Abstract
A 38‐year‐old woman with type 1 diabetes underwent kidney‐pancreas transplantation. Her postoperative course was complicated due to recurrent acute graft rejections and pancreatitis. After initial immunosuppression with microemulsion cyclosporine, mycophenolate mofetil, and prednisone with muromonab‐CD3 induction, cyclosporine was switched to tacrolimus on day 44. The initial dosage was 5 mg twice/day, but it was gradually increased to 10 mg twice/day, aiming at 15–20 ng/ml. On day 17 of tacrolimus therapy the woman developed sudden hearing loss with tinnitus. The serum tacrolimus level was 28.3 ng/ml (therapeutic range 10–20 ng/ml) on day 20 of tacrolimus therapy, and peaked at 34.9 ng/ml on day 28. Two audiograms performed on days 28 and 29 confirmed bilateral hearing loss of 80% for speech perception, characterized as mild to moderate sensorineural hearing loss with speech reception threshold of 35 dB (normal < 20 dB) in both ears. The tacrolimus dosage was gradually reduced to 6 mg twice/day by day 36, with drug level 9.7 ng/ml, after which her hearing gradually recovered.Keywords
This publication has 9 references indexed in Scilit:
- Neural actions of immunophilin ligandsTrends in Pharmacological Sciences, 1998
- FK506 and the role of immunophilins in nerve regenerationMolecular Neurobiology, 1997
- Reversible Sensorineural Hearing Loss after Renal Transplant Immunosuppression with OKT3 (MUROMONAB-CD3)Annals of Otology, Rhinology & Laryngology, 1997
- Ototoxic Effect of Erythromycin on Cochlear Potentials in the Guinea PigAnnals of Otology, Rhinology & Laryngology, 1997
- Inhibitory Effect of Erythromycin on Ion Transport by Stria Vascularis and Vestibular Dark CellsActa Oto-Laryngologica, 1996
- Tacrolimus: a new immunosuppressive agentAmerican Journal of Health-System Pharmacy, 1995
- Clinically Significant Hearing Loss in Renal Allograft Recipients Treated With Intravenous ErythromycinArchives of internal medicine (1960), 1993
- Erythromycin ototoxicity: Prospective assessment with serum concentrations and audiograms in a study of patients with pneumoniaThe American Journal of Medicine, 1992
- Erythromycin Ototoxicity: Analysis and Conclusions Based on 22 Case ReportsOtolaryngology–Head and Neck Surgery, 1984